
|Videos|July 2, 2015
Avelumab in Patients With Relapsed or Recurrent Ovarian Cancer
Author(s)Jeffrey Infante, MD
Jeffrey Infante, MD, director, Drug Development Program, Sarah Cannon Research Institute, discusses a phase Ib, open-label expansion trial examining avelumab for the treatment of patients with previously treated, recurrent or refractory ovarian cancer.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts NDA for 177Lu-edotreotide in GEP-NETs
2
Rethinking Advanced Prostate Cancer: Surprising Finds from a Landmark Study
3
Long-Term Follow-Up Confirms Benefits of Low-Dose Seminoma Treatment
4
FDA Authorizes EXENT System to Aid Myeloma Diagnosis
5









































